Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Sous-étude KEYMAKER-U01 01J : Une étude du pembrolizumab plus MK-1084 chez des participants atteints d'un cancer du poumon non à petites cellules (CPNPC) avec des mutations de l'oncogène viral du sarcome de rat Kirsten (KRAS) G12C (MK-3475-01J/KEYMAKER-U01J)

6 novembre 2026 mis à jour par: Merck Sharp & Dohme LLC

KEYMAKER-U01 Sous-étude 01J : Une étude de phase 2 randomisée en parapluie avec bras tournants d'agents expérimentaux pour le traitement de première ligne de participants atteints d'un cancer du poumon non à petites cellules (CPNPC) non squameux avancé ou métastatique avec mutations KRAS G12C

Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

140

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chili, 7560908
        • Recrutement
        • Centro de Oncología de Precisión ( Site 0160)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +56991612199
      • Santiago, Region M. de Santiago, Chili, 7500921
        • Recrutement
        • Fundacion Arturo Lopez Perez ( Site 0167)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 56224205098
      • Santiago, Region M. de Santiago, Chili, 8420383
        • Recrutement
        • Bradfordhill ( Site 0168)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +56998744662
    • Jiangsu
      • Nanjing, Jiangsu, Chine, 210000
        • Recrutement
        • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +8602568182222
    • Jiangxi
      • Nanchang, Jiangxi, Chine, 330209
        • Recrutement
        • The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0306)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +86 791 8631 9333
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine, 200032
        • Recrutement
        • Zhongshan Hospital Fudan University ( Site 0319)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +8615000229853
    • Sichuan
      • Chengdu, Sichuan, Chine, 610066
        • Recrutement
        • West China Hospital, Sichuan University ( Site 0315)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +8618980602252
      • Seoul, Corée du Sud, 03722
        • Recrutement
        • Severance Hospital Yonsei University Health System ( Site 0080)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +82222280880
      • Seville, Espagne, 41009
        • Recrutement
        • Hospital Universitario Virgen de la Macarena ( Site 0093)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +34 671560092
    • Northern Savonia
      • Kuopio, Northern Savonia, Finlande, 70200
        • Recrutement
        • Kuopion Yliopistollinen Sairaala ( Site 0261)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +35817173311
    • Pohjanmaa
      • Vaasa, Pohjanmaa, Finlande, 65130
        • Recrutement
        • Vaasan Keskussairaala ( Site 0263)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +358405533545
    • Southwest Finland
      • Turku, Southwest Finland, Finlande, 20520
        • Recrutement
        • Turku University Hospital ( Site 0262)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +35823138709
    • Uusimaa
      • Helsinki, Uusimaa, Finlande, 00290
        • Recrutement
        • HYKS Syöpätautien klinikka ( Site 0260)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +358406682951
    • Attica
      • Athens, Attica, Grèce, 106 76
        • Recrutement
        • Evangelismos General Hospital of Athens ( Site 0200)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +302132041631
      • Central, Hong Kong, 0000
        • Recrutement
        • Hong Kong Integrated Oncology Centre ( Site 0232)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +85237006888
      • Hong Kong, Hong Kong
        • Recrutement
        • Queen Mary Hospital ( Site 0230)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +85222551727
      • Kowloon, Hong Kong
        • Recrutement
        • Hong Kong United Oncology Centre ( Site 0231)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +852 2386 8002
    • Lombardy
      • Milan, Lombardy, Italie, 20133
        • Recrutement
        • Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 00390223903829
    • Overijssel
      • Deventer, Overijssel, Pays-Bas, 7416 SE
        • Recrutement
        • Deventer Ziekenhuis ( Site 0272)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +31570536437
    • South Holland
      • Leiden, South Holland, Pays-Bas, 2333 ZA
        • Recrutement
        • Leids Universitair Medisch Centrum ( Site 0273)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +31715566376
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Pologne, 02-781
        • Recrutement
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 48 22 546 23 36
    • Bangkok
      • Bangkok, Bangkok, Thaïlande, 10300
        • Recrutement
        • Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0351)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +6622443461
      • Bangkok, Bangkok, Thaïlande, 10700
        • Recrutement
        • Faculty of Medicine Siriraj Hospital ( Site 0350)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +6624194488-9
      • Adana, Turquie (Türkiye), 34010
        • Recrutement
        • Koç Üniversitesi Hastanesi ( Site 0142)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 08502508250-21251
      • Adana, Turquie (Türkiye), 1250
        • Recrutement
        • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +905537766235
      • Ankara, Turquie (Türkiye), 6230
        • Recrutement
        • Hacettepe Universite Hastaneleri ( Site 0140)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +90 312 305 50 00
      • Ankara, Turquie (Türkiye), 06680
        • Recrutement
        • Liv Hospital Ankara ( Site 0146)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 905469299990
    • Kayseri
      • Talas, Kayseri, Turquie (Türkiye), 38039
        • Recrutement
        • Erciyes University ( Site 0145)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 905366550924
      • Kyiv, Ukraine, 03022
        • Actif, ne recrute pas
        • VISION PARTNER Medical Centre ( Site 0135)
      • Kyiv, Ukraine, 03151
        • Recrutement
        • LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 0138)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +380671502987
    • Cherkasy Oblast
      • Cherkasy, Cherkasy Oblast, Ukraine, 18009
        • Recrutement
        • COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0139)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +380472370123
    • Dnipropetrovsk Oblast
      • Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine, 50000
        • Recrutement
        • Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 0465)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +380677490687
    • Ivano-Frankivsk Oblast
      • Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine, 76018
        • Recrutement
        • Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0132)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 380978411455
    • Kirovohrad Oblast
      • Kropyvnytskyi, Kirovohrad Oblast, Ukraine, 25011
        • Recrutement
        • Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 0467)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +380958718674
    • Lviv Oblast
      • Lviv, Lviv Oblast, Ukraine, 79059
        • Recrutement
        • Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 0133)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +380677724757
    • Vinnytsia Oblast
      • Vinnitsya, Vinnytsia Oblast, Ukraine, 21029
        • Recrutement
        • Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 0131)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 380953105783
    • Zakarpattia Oblast
      • Uzhhorod, Zakarpattia Oblast, Ukraine, 88000
        • Recrutement
        • Uzhhorod Municipal Multidisciplinary Clinical Hospital of Uzhhorod City Council ( Site 0137)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +380506847086
    • Florida
      • Clermont, Florida, États-Unis, 34711
        • Recrutement
        • Clermont Oncology Center ( Site 0041)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 386-538-3169
    • North Dakota
      • Fargo, North Dakota, États-Unis, 58102
        • Recrutement
        • Sanford Health Roger Maris Cancer Center ( Site 0039)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 701-234-2000
    • South Dakota
      • Sioux Falls, South Dakota, États-Unis, 57104
        • Recrutement
        • Sanford Cancer Center Oncology Clinic ( Site 0038)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 605-328-8000

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has histologically or cytologically confirmed diagnosis of advanced or metastatic nonsquamous Non-Small Cell Lung Cancer (NSCLC)
  • Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations
  • Can provide an archival tumor tissue sample or newly obtained core, incisional, excisional biopsy of a tumor lesion not previously irradiated
  • Has recovered to ≤Grade 1 or baseline from any Adverse events (AEs) due to previous anticancer therapies and/or ≤Grade 2 neuropathy and/or endocrine-related AEs adequately treated with hormone replacement
  • Has well controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if HIV-infected
  • Has undetectable hepatitis B (HBV) viral load and have received HBV antiviral therapy for at least 4 weeks if hepatitis B surface antigen (HBsAg) positive
  • Has undetectable hepatitis C (HCV) viral load if HCV-infected

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
  • Has HIV-infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
  • Has uncontrolled, clinically significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval corrected for heart rate by Fridericia's formula (QTcF) interval to >470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
  • Has received prior systemic anticancer therapy for advanced or metastatic NSCLC
  • Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
  • Has received previous treatment with an agent targeting KRAS
  • Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) and has not recovered to grade ≤ 1 or baseline from AE associated with anticancer therapy before allocation/randomization
  • Has received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
  • Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has a known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening
  • Has a history of stem cell/solid organ transplant
  • Has not adequately recovered from major surgery or has ongoing surgical complications

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Arm A- Pembrolizumab + MK-1084

Participants receive 400 mg of Pembrolizumab every 6 weeks and MK-1084 dose regimen.

Oral Administration

Intravenous administration

Autres noms:
  • Keytruda
  • MK-3475
Expérimental: Arm B- Pembrolizumab + MK-1084 + Cetuximab

Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and Cetuximab 500 mg/m^2 every 2 weeks.

Intravenous administration

Oral Administration

Intravenous administration

Autres noms:
  • Keytruda
  • MK-3475
Expérimental: Arm C- Pembrolizumab + MK-1084 + sacituzumab tirumotecan (sac-TMT)

Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and 4 mg/kg sacituzumab tirumotecan (sac-TMT) every 2 weeks.

Oral Administration

Intravenous administration

Autres noms:
  • Keytruda
  • MK-3475

Injection powder for intravenous infusion

Autres noms:
  • SKB264
  • MK-2870

Participants receive the following rescue medications, per approved product label, as premedication to study treatment to prevent hypersensitivity and/or infusion reactions: diphenhydramine (or equivalent histamine-1 [Hl] receptor antagonist), H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, and granulocyte colony-stimulating factor (G-CSF). A steroid mouthwash (dexamethasone or equivalent) will be given as prophylaxis for stomatitis/oral mucositis.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of Participants with a Dose Limiting Toxicity (DLT)
Délai: Up to approximately 21 days

A DLT is defined as the occurrence of protocol-specified toxicities if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration, excluding toxicities clearly not related to the drug.

Up to approximately 21 days
Percentage of Participants who Experience at Least One Adverse Event (AE)
Délai: Up to approximately 84 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 84 months
Percentage of Participants who Discontinue Study Intervention Due to an AE
Délai: Up to approximately 84 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Up to approximately 84 months
Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review (BICR)
Délai: Up to approximately 84 months

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented.

Up to approximately 84 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Duration of Response (DOR) per RECIST 1.1 as assessed by BICR
Délai: Up to approximately 84 months

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

Up to approximately 84 months
Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR
Délai: Up to approximately 84 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

Up to approximately 84 months
Overall Survival (OS)
Délai: Up to approximately 84 months

OS, defined as the time from first dose or randomization (depending on study period) to death due to any cause. OS will be presented.

Up to approximately 84 months
Area Under the Concentration-Time Curve (AUC) for MK-1084
Délai: At designated timepoints (up to approximately 44 days)

Blood samples will be collected to determine the AUC of MK-1084.

At designated timepoints (up to approximately 44 days)
Maximum Concentration (Cmax) of MK-1084
Délai: At designated timepoints (up to approximately 44 days)

Blood samples will be collected to estimate Cmax of MK-1084.

At designated timepoints (up to approximately 44 days)
Trough Concentration (Ctrough) of MK-1084
Délai: At designated timepoints (up to approximately 84 months)

Blood samples will be collected to determine the Ctrough of MK-1084.

At designated timepoints (up to approximately 84 months)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Medical Director, Merck Sharp & Dohme LLC

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

19 décembre 2025

Achèvement primaire (Estimé)

15 novembre 2029

Achèvement de l'étude (Estimé)

31 mai 2032

Dates d'inscription aux études

Première soumission

20 novembre 2025

Première soumission répondant aux critères de contrôle qualité

20 novembre 2025

Première publication (Réel)

28 novembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

6 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner